Cheloni et al. reported acriflavine, a HIF-1 inhibitor, targets CML LSCs by reducing MYC and decreases stemness-related genes such as NANOG, SOX2, and OCT4 by decreasing HIF-2α. Here, HIF1A is linked to chronic myelogenous leukemia, BCR-ABL1 positive.